Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches

EP: 1.The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients

EP: 2.Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape

EP: 3.First-Line HER2+ Metastatic Breast Cancer Trials in Focus

EP: 4.Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd

EP: 5.Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates

EP: 6.Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer

EP: 7.TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting

Now Viewing

EP: 8.Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches

EP: 9.Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses

EP: 10.Managing Brain Metastases in HER2+ Metastatic Breast Cancer: Clinical Trial Data and Multidisciplinary Approaches

EP: 11.Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

Video content above is prompted by the following questions:

• Patient Case: A 54-year-old woman with HER2+ metastatic breast cancer and brain metastases
  • Please describe your initial impressions of this case. How might you have treated this patient in your practice?
• Per the NCCN guidelines, what is the preferred treatment approach for this patient/patients with systemic and CNS progression?
• In which lines of therapy do the NCCN guidelines recommend using the tucatinib + trastuzumab + capecitabine regimen for patients with brain metastases?
• Please discuss the differences between active and stable brain metastases and how these factors influence your treatment decisions.
  • At what points during metastatic breast cancer treatment do you typically screen for brain metastases?
  • How do you view the role of systemic therapy versus local therapy in the management of brain metastases in HER2-positive mBC?